Analysts rate Spectrum Pharmaceuticals Inc. (SPPI:NSD) with a Strong Buy rating and a $10 target

STA Research
by: STA Research
SPPI stock

Based on the Spectrum Pharmaceuticals stock forecast from 3 analysts, the average analyst SPPI stock price target is USD 10.33 over the next 12 months. Spectrum Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of SPPI stock forecast is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Spectrum Pharmaceuticals stock price was USD 0.66Spectrum Pharmaceuticals stock price has changed by -0.51% over the past week, -0.61% over the past month and -71.79% over the last year.

 

About Spectrum Pharmaceuticals Inc. (SPPI:NSD):

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company’s products under development include Eflapegrastim, Poziotinib, and Anti-CD20-IFNa. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

 

Most Recent Analyst Ratings for SPPI’s stock:

Target Lowered by HC Wainwright Buy USD 12 » USD 9 2022-09-20
Maintains HC Wainwright Buy USD 10 » USD 12 2022-09-12
Reiterated by HC Wainwright Buy USD 10 2022-05-29
Reiterated by Cantor Fitzgerald Securities Neutral 2022-04-02
Target Lowered by B. Riley Buy USD 6 » USD 4 2022-03-21
Reiterated by JMP Securities Buy USD 4 2021-09-20
Target Lowered by B. Riley Buy USD 8 » USD 6 2021-08-18
Initiated by JMP Securities Outperform USD 12 2020-09-17
Target Raised by HC Wainwright Buy USD 11 » USD 13 2020-08-03
Target Raised Cantor Positive » Neutral USD 4 » USD 7 2020-07-28
Target Lowered by B. Riley Buy USD 11 » USD 8 2020-03-02
Downgrades Guggenheim Neutral 2019-12-27
Downgrades Guggenheim Securities Neutral 2019-12-27
Maintains B. Riley Buy USD 18 » USD 11 2019-12-27
Reiterated by Cantor Overweight » Neutral USD 17 » USD 4 2019-12-26
Reiterated by HC Wainwright Buy USD 41 » USD 11 2019-12-26
Downgraded by Guggenheim Securities Buy » Neutral 2019-12-26
Reiterates HC Wainwright Buy 2019-10-25
Initiated B. Riley Buy USD 18 2019-07-11
Initiates Coverage On Guggenheim Securities Buy USD 19 2019-05-13
Reiterates Jefferies Financial LLC Buy » Buy USD 21 2019-03-15
Initiates Cantor Fitzgerald Securities Overweight USD 19 2019-02-07
Reiterates HC Wainwright Buy USD 40 2019-01-10
Lowers Target B. Riley Buy USD 21 2018-12-20
Reiterated B. Riley Buy USD 35 2018-11-12

 

 

What we like:

There is nothing we particularly like about SPPI stock.

 

What we don’t like:

Poor risk-adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns, the returns are unpredictable. Proceed with caution.

Below median dividend returns

The average income yield of SPPI stock over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

SPPI stock price is trading high compared to its peers median on a price to book value basis.

Negative cashflow

Spectrum Pharmaceuticals stock had negative total cash flow in the most recent four quarters.

Negative free cash flow

SPPI stock had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

SPPI stock has shown below median revenue growth in the previous 5 years compared to its sector.

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.